VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development
Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science. Despite significant advances in artificial intelligence and computational chemistry, the fundamental translational gap between preclinical models and human clinical outcomes persists, contributing to late-stage failure rates that cost the industry hundreds of billions of dollars annually.
VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has been selected as the winner of the “Predictive Analytics Solution of the Year" in this year’s BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates.
VeriSIM Life CEO Dr. Jo Varshney Shares Pioneering Approach to Business and Life with MSNBC Mika Brzezinski's Know Your Value Platform
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, is pleased to announce that its CEO, Dr. Jo Varshney, is featured on MSNBC’s Know Your Value platform where she discussed with Mika Brzezinski, co-host of MSNBC’s Morning Joe, her professional and personal experiences that have shaped her path to becoming CEO of VeriSIM Life. Know Your Value is spearheaded by Ms. Brzezinski as an empowered community that helps women recognize and be recognized for their personal and professional value by developing and inspiring their individual growth.
VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders.
VeriSIM Life Announces Acquisition of Molomics Biotech
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in clinical trials.
VeriSIM Life Awarded Federal Grant from National Institutes of Health for Substance Use Disorder Drug Discovery and Development
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced today it has been awarded a $312,310 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund AI-driven development of medications for substance use disorder (SUD). VeriSIM and UF Scripps Biomedical Research scientist Courtney Miller, Ph.D. will collaborate on the research and drug discovery project. Research reported in this announcement was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number 1R43DA056084-01.
VeriSIM Life to Present at Biotech Showcase and Participate in BIO Partnering at JPM Week
VeriSIM Life www.verisimlife.com, an artificial intelligence-driven bio-pharma technology company with a mission to advance human health by accelerating drug development, today announced its founder and CEO, Jo Varshney, DVM, PhD, will give a corporate presentation at the virtual Biotech Showcase being held January 10-19, 2022. VeriSIM Life will also participate in the BIO @ JPM partnering events and the JPM Healthcare Conference on January 10-14, 2022.
VeriSIM Life Secures $15 Million Series A Funding
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced it has closed its oversubscribed $15 million Series A round. The financing was led by Morpheus Ventures. Additional new investors include Debiopharm Innovation Fund and Colorcon Ventures, with continued support from existing investors OCA Ventures, Intel Capital, Serra Ventures and Susa Ventures.
